Clinical Trial Update: A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Palbociclib (PD-0332991) in recurrent RB-positive glioblastoma was terminated. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: TERMINATED | Results posted: 2015-06-12